Table 1.
Disease classification | Small molecule compounds | Synthetic devices | Regulating elements | Output effects | Cell lines | Refs |
---|---|---|---|---|---|---|
Bacterial infectious diseases | 2-phenylethyl-butyrate | DNA | EthR | Increasing sensitivity to drug | HEK-293 cells | Weber et al., 2008 |
Immunity diseases | Leucovorin (6R)- folinic acid | DNA | miRNA | Modulating T cell proliferation | T cells | Wong et al., 2018 |
Doxycycline | DNA | Tetracycline inducible promoter (pTRE) | Disabling T cell activation temporarily | T cells | Wei et al., 2012 | |
Theophylline | RNA | Ribozyme | Controlling cell proliferation | mouse and primary human T cells | Chen et al., 2010 | |
Metabolic diseases | Guanabenz | DNA | Chimeric trace amine-associated receptor | Stimulating the secretion of active peptides | HEK-293 cells, Hela, Hana3A cells and CHO-K1 | Ye et al., 2013 |
Cytosine arabinoside (Ara-C) | DNA | The luxCDABE operon | Detecting the transition between Ara-C and Ara-CTP | E. coli MG1655 | Alloush et al., 2010 | |
Phloretin | DNA | Bacterial DNA-binding repressor TtgR | Inhibiting the downstream transgene expression | HEK-293 cells, BHK-21, COS-7, CHO-K1, Hela, HT-1080 and human mesenchymal stem cells | Rossger et al., 2013 | |
Protocatechuic acid (PCA) | DNA | KRAB-PcaV transrepressor fusion protein | Increasing the insulin level and lowering the blood glucose concentrations | HEK-293 cells, HeLa, human telomerase-immortalised mesenchymal stem cells, mouse myoblast cells (C2C12), and HEK-293-derived Hana3A cells | Yin et al., 2019 | |
Cancers | Ganciclovir | DNA | Herpes simplex virus-thymidine kinase | Inducing cell apoptosis | HEK-293 cells | Culler et al., 2010 |
4-hydroxytamoxifen (4-OHT) | DNA | The estrogen receptor ligand binding domain (ERT2) | Controlling CAR expression and T cell activity | Jurkat T cells | Chakravarti et al., 2019 | |
4-hydroxytamoxifen (4-OHT) | DNA | ERT2-CreN-nMag | Controlling CAR expression and T cell activity | HEK293T cells, Jurkat T cells (Clone E6-1, TIB-152), K-562 lymphoblasts (CCL-243, CD38-/CD19- target cells), and Toledo B lymphocytes | Allen et al., 2019 | |
Doxycycline, Trimethoprim |
RNA | Tetracycline-responsive repressor and E. coli dihydrofolate reductase | Controlling the expression of fusion proteins | BHK-21 cells and C2C12 mouse myoblasts | Wagner et al., 2018 | |
Theophylline | RNA | Ribozyme | Causing cell cycle arrest | U2-OS cells and HEK-293 cells | Wei and Smolke, 2015 |